Does Rallies show Form 4 insider transactions for OKUR?

Yes. Rallies tracks OKUR insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is OKUR research on Rallies investment advice?

No. Rallies provides research, data, and educational context for OKUR. It does not provide personalized investment advice.

OKUR (OnKure Therapeutics, Inc. Class A Common Stock) Stock Analysis - Insider Trades

OnKure Therapeutics, Inc. Class A Common Stock (OKUR) is a publicly traded Healthcare sector company. As of May 21, 2026, OKUR trades at $3.64 with a market cap of $124.42M and a P/E ratio of -0.83. OKUR moved +8.18% today. Year to date, OKUR is +24.04%; over the trailing twelve months it is +53.45%. Its 52-week range spans $1.70 to $20.00. Analyst consensus is strong buy with an average price target of $24.33. Rallies surfaces OKUR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading OKUR stock inside the company?

Recent OKUR insider activity includes Saccomano Nicholas A sold 86, Leverone Jason A. sold 301, Saccomano Nicholas A sold 87, Leverone Jason A. sold 302, and Saccomano Nicholas A sold 88. Rallies tracks insider transaction dates, shares, prices, and estimated values.

OKUR Key Metrics

Key financial metrics for OKUR
Metric	Value
Price	$3.64
Market Cap	$124.42M
P/E Ratio	-0.83
EPS	$-4.33
Dividend Yield	0.00%
52-Week High	$20.00
52-Week Low	$1.70
Volume	17
Avg Volume	0
Revenue (TTM)	$2.82M
Net Income	$-58.75M
Gross Margin	0.00%

Recent OKUR Insider Trades

Saccomano Nicholas A sold 86 (~$357.459) on Mar 23, 2026.
Leverone Jason A. sold 301 (~$1.25K) on Mar 23, 2026.
Saccomano Nicholas A sold 87 (~$258.19) on Dec 22, 2025.
Leverone Jason A. sold 302 (~$896.245) on Dec 22, 2025.
Saccomano Nicholas A sold 88 (~$230.868) on Sep 22, 2025.

Latest OKUR News

OnKure Secures $150M, Advances OKI-355 and OKI-345 Candidates — May 5, 2026
OnKure Raises $150M to Fund PI3Kα Inhibitor IND Filings in 2027 — Mar 27, 2026
OnKure Therapeutics Reports $59.1M Cash, Reduces Q4 Loss to $13.5M — Mar 12, 2026

OKUR Analyst Consensus

4 analysts cover OKUR: 0 strong buy, 3 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $24.33.

Common questions about OKUR

Who is trading OKUR stock inside the company?: Recent OKUR insider activity includes Saccomano Nicholas A sold 86, Leverone Jason A. sold 301, Saccomano Nicholas A sold 87, Leverone Jason A. sold 302, and Saccomano Nicholas A sold 88. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for OKUR?: Yes. Rallies tracks OKUR insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is OKUR research on Rallies investment advice?: No. Rallies provides research, data, and educational context for OKUR. It does not provide personalized investment advice.